TransMedics Group (NASDAQ:TMDX) Posts Quarterly Earnings Results, Beats Expectations By $2.21 EPS

TransMedics Group (NASDAQ:TMDX) issued its quarterly earnings data on Tuesday. The company reported $2.62 EPS for the quarter, beating analysts’ consensus estimates of $0.41 by $2.21, FiscalAI reports. TransMedics Group had a return on equity of 31.42% and a net margin of 16.20%.The business had revenue of $160.76 million for the quarter, compared to analyst estimates of $155.28 million.

TransMedics Group Stock Performance

NASDAQ TMDX traded up $3.13 during midday trading on Tuesday, hitting $137.78. The company had a trading volume of 1,178,037 shares, compared to its average volume of 722,154. The firm has a fifty day simple moving average of $132.73 and a two-hundred day simple moving average of $126.05. TransMedics Group has a fifty-two week low of $62.07 and a fifty-two week high of $156.00. The company has a quick ratio of 7.13, a current ratio of 7.69 and a debt-to-equity ratio of 1.43. The stock has a market cap of $4.71 billion, a price-to-earnings ratio of 55.78 and a beta of 2.06.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the company. Canaccord Genuity Group upped their target price on TransMedics Group from $147.00 to $148.00 and gave the stock a “buy” rating in a research report on Wednesday, December 17th. Wall Street Zen upgraded shares of TransMedics Group from a “hold” rating to a “buy” rating in a research note on Saturday, February 14th. Needham & Company LLC raised their target price on shares of TransMedics Group from $148.00 to $166.00 and gave the company a “buy” rating in a research note on Monday, December 8th. Piper Sandler reiterated an “overweight” rating on shares of TransMedics Group in a report on Monday, December 22nd. Finally, Morgan Stanley upped their price target on shares of TransMedics Group from $123.00 to $135.00 and gave the company an “equal weight” rating in a report on Tuesday, December 2nd. Six equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, TransMedics Group currently has a consensus rating of “Moderate Buy” and an average price target of $144.25.

Insider Activity

In other TransMedics Group news, CFO Gerardo Hernandez sold 920 shares of the company’s stock in a transaction that occurred on Thursday, December 4th. The stock was sold at an average price of $139.62, for a total value of $128,450.40. Following the completion of the transaction, the chief financial officer owned 15,064 shares of the company’s stock, valued at $2,103,235.68. This represents a 5.76% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director David Weill sold 5,000 shares of TransMedics Group stock in a transaction that occurred on Wednesday, December 3rd. The stock was sold at an average price of $138.64, for a total value of $693,200.00. Following the sale, the director directly owned 12,134 shares in the company, valued at $1,682,257.76. The trade was a 29.18% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 7.00% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Parallel Advisors LLC boosted its stake in TransMedics Group by 42.1% during the fourth quarter. Parallel Advisors LLC now owns 280 shares of the company’s stock worth $34,000 after buying an additional 83 shares in the last quarter. Canada Pension Plan Investment Board lifted its holdings in shares of TransMedics Group by 2.9% during the 2nd quarter. Canada Pension Plan Investment Board now owns 3,600 shares of the company’s stock worth $482,000 after acquiring an additional 100 shares during the period. US Bancorp DE boosted its position in shares of TransMedics Group by 24.2% during the 3rd quarter. US Bancorp DE now owns 533 shares of the company’s stock valued at $60,000 after acquiring an additional 104 shares in the last quarter. Smartleaf Asset Management LLC increased its stake in TransMedics Group by 24.5% in the second quarter. Smartleaf Asset Management LLC now owns 548 shares of the company’s stock valued at $72,000 after acquiring an additional 108 shares during the period. Finally, Summit Global Investments increased its stake in TransMedics Group by 3.6% in the fourth quarter. Summit Global Investments now owns 3,260 shares of the company’s stock valued at $397,000 after acquiring an additional 112 shares during the period. 99.67% of the stock is currently owned by institutional investors and hedge funds.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.